Christopher Cann

1.0k total citations · 1 hit paper
27 papers, 447 citations indexed

About

Christopher Cann is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Christopher Cann has authored 27 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 5 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Christopher Cann's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Genomics and Diagnostics (3 papers). Christopher Cann is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (3 papers) and Cancer Genomics and Diagnostics (3 papers). Christopher Cann collaborates with scholars based in United States, Australia and United Kingdom. Christopher Cann's co-authors include R. L. Prince, Benjamin Khoo, Kexiang Zhu, Cathy Eng, Roger I. Price, J.K. Brown, V H Low, Rodrigo Oliva Perez, Chiara Cremolini and Erika Ruíz‐García and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Christopher Cann

22 papers receiving 434 citations

Hit Papers

Colorectal cancer 2024 2026 2025 2024 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Colorectal cancer
    2024 126 citations Cathy Eng, Takayuki Yoshino et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christopher Cann United States 10 139 116 101 78 77 27 447
Maxine H. Dorin United States 11 59 0.4× 166 1.4× 89 0.9× 50 0.6× 32 0.4× 18 761
Taj M. Kattapuram United States 8 55 0.4× 100 0.9× 24 0.2× 56 0.7× 51 0.7× 17 306
A. Rodin United Kingdom 10 213 1.5× 56 0.5× 103 1.0× 25 0.3× 43 0.6× 12 396
S. Schmidt Germany 10 124 0.9× 71 0.6× 38 0.4× 53 0.7× 80 1.0× 12 550
Simonetta Massaron Italy 11 12 0.1× 211 1.8× 103 1.0× 68 0.9× 130 1.7× 21 478
D. Flores Mexico 5 62 0.4× 80 0.7× 81 0.8× 13 0.2× 14 0.2× 8 390
Manuel Post Germany 11 15 0.1× 171 1.5× 41 0.4× 23 0.3× 135 1.8× 21 652
David J. Kirby United States 11 34 0.2× 180 1.6× 31 0.3× 15 0.2× 60 0.8× 37 361
Chunyan Xing China 8 40 0.3× 84 0.7× 24 0.2× 12 0.2× 63 0.8× 17 283
N Martin Spain 8 99 0.7× 108 0.9× 281 2.8× 124 1.6× 67 0.9× 18 482

Countries citing papers authored by Christopher Cann

Since Specialization
Citations

This map shows the geographic impact of Christopher Cann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Cann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Cann more than expected).

Fields of papers citing papers by Christopher Cann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Cann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Cann. The network helps show where Christopher Cann may publish in the future.

Co-authorship network of co-authors of Christopher Cann

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Cann. A scholar is included among the top collaborators of Christopher Cann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Cann. Christopher Cann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Ruizhi, et al.. (2026). Trifluridine–Tipiracil with and without Bevacizumab in Colorectal Cancer. NEJM Evidence. 5(3). EVIDoa2500120–EVIDoa2500120.
2.
3.
4.
Kennecke, Hagen F., Christopher J. O’Callaghan, Dongsheng Tu, et al.. (2024). The NEO-RT trial: A phase 3 randomized trial of neoadjuvant chemotherapy, excision and observation versus chemoradiotherapy for early rectal cancer, CCTG CO.32.. Journal of Clinical Oncology. 42(16_suppl). TPS3646–TPS3646. 1 indexed citations
5.
Cann, Christopher, Chan Shen, Dana B. Cardin, et al.. (2024). Palliative and supportive care underutilization for patients with locally advanced pancreatic cancer: review of the NCDB. SHILAP Revista de lepidopterología. 4. 100049–100049.
6.
Eng, Cathy, Takayuki Yoshino, Erika Ruíz‐García, et al.. (2024). Colorectal cancer. The Lancet. 404(10449). 294–310. 126 indexed citations breakdown →
7.
Cann, Christopher, et al.. (2023). Molecular and genetic targets within metastatic colorectal cancer and associated novel treatment advancements. Frontiers in Oncology. 13. 1176950–1176950. 6 indexed citations
8.
Cann, Christopher, et al.. (2022). Two Uncomplicated Pregnancies on Alectinib in a Woman With Metastatic ALK-Rearranged NSCLC: A Case Report. JTO Clinical and Research Reports. 3(8). 100361–100361. 6 indexed citations
9.
Shen, Chan, Erin A. Gillaspie, Christopher Cann, et al.. (2022). Variation in Treatment Patterns of Patients with Early-Onset Gastric Cancer. Cancers. 14(15). 3633–3633. 8 indexed citations
10.
11.
Bai, Xue, Alexander N. Shoushtari, Allison Betof Warner, et al.. (2021). Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).. Journal of Clinical Oncology. 39(15_suppl). 9530–9530. 1 indexed citations
12.
Iams, Wade T., Prasad Kopparapu, Yingjun Yan, et al.. (2020). Blood-Based Surveillance Monitoring of Circulating Tumor DNA From Patients With SCLC Detects Disease Relapse and Predicts Death in Patients With Limited-Stage Disease. JTO Clinical and Research Reports. 1(2). 100024–100024. 16 indexed citations
13.
Cann, Christopher, et al.. (2019). Empiric Therapy with BRAF and MEK Inhibitors in Metastatic Melanoma. The Oncologist. 24(11). 1495–1496. 1 indexed citations
14.
Cann, Christopher, et al.. (2017). Sedation in intensive care: should we reach for dexmedetomidine sooner?. British Journal of Hospital Medicine. 78(10). 598–598. 2 indexed citations
15.
Cann, Christopher, Rinn Song, & Ruth M. Ruprecht. (2005). Antibodies: Can They Protect Against HIV Infection?. PubMed. 5(2). 95–111. 28 indexed citations
16.
Cann, Christopher, et al.. (1992). Pathophysiology of mineral loss during space flight. Bone and Mineral. 17. 227–227. 3 indexed citations
17.
Gamsu, G, et al.. (1987). A Preliminary Study of MRI Quantification of Simulated Calcified Pulmonary Nodules. Investigative Radiology. 22(11). 853–858. 14 indexed citations
18.
Jaschke, Werner, et al.. (1985). Dynamic CT scanning of the normal canine liver: interpretation of time density curves resulting from an intravenous bolus injection of contrast material.. PubMed. 5(4). 256–60. 9 indexed citations
19.
Ringertz, Hans, Brian Rodgers, Martin J. Lipton, Christopher Cann, & Erik Carlsson. (1985). Assessment of Human Right Ventricular Cast Volume by CT and Angiocardiography. Investigative Radiology. 20(1). 29–32. 13 indexed citations
20.
Cann, Christopher, et al.. (1976). Bone Formation Rate in Experimental Disuse Osteoporosis in Monkeys. 19(3). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maxine H. Dorin Breakdown of academic impact, for papers by Taj M. Kattapuram Breakdown of academic impact, for papers by A. Rodin Breakdown of academic impact, for papers by S. Schmidt Breakdown of academic impact, for papers by Simonetta Massaron Breakdown of academic impact, for papers by D. Flores Breakdown of academic impact, for papers by Manuel Post Breakdown of academic impact, for papers by David J. Kirby Breakdown of academic impact, for papers by Chunyan Xing Breakdown of academic impact, for papers by N Martin
Rankless by CCL
2026